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ABSTRACT

HPV vaccination is routinely recommended for young adult women aged 1826 regardless of previous sexual activity or history of HPV-related disease. As of
2010, only 21% of US women had received ≥1 doses of HPV vaccine. The objective
of this study was to describe United States (US) women aged 18-26 who do not
initiate vaccination and identify a minimum subset of variables to develop a predictive
model of non-vaccination. Data from the 2010 National Health Interview Survey
Adult Cancer Supplement were used to examine US women aged 18-26 (N=1,866).
Descriptive statistics, univariate procedures, and multivariate logistic regression were
conducted. Results indicate that 78% of eligible women did not receive vaccination,
and 35% of unvaccinated women were not aware of the vaccine. Eight variables were
retained for the final model (age aOR=2.93, 95% CI=2.00, 4.30; marital status
aOR=1.75, 95% CI=1.02, 3.01; live birth in the past 5 years aOR=2.77, 95% CI=1.75,
4.39, current birth control use aOR=0.45, 95% CI=0.31, 0.64; region aOR=0.50, 95%
CI=0.31, 0.79; recent doctor’s visit aOR=0.45, 95% CI=0.39-0.84; flu shot receipt
aOR=0.36, 95% CI=0.24, 0.54; tetanus shot receipt aOR=0.40, 95% CI=0.26, 0.62).
This model showed good fit to the data (Hosmer-Lemeshow chi-square=14.41(8);
p=0.07; max rescaled R-square=0.27; c statistic=0.80). These findings show that older
age, being married, having children, living in the South, and not receiving other
preventive health services are associated with non-vaccination. These findings identify
a subgroup of at-risk women who might benefit from targeted vaccine promotion
campaigns to increase HPV vaccine uptake.
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INTRODUCTION

Human papillomavirus (HPV) is the most common sexually transmitted
infection in the United States (CDCa, 2012). It is estimated that 80% of sexually
active females will be exposed to HPV before they reach 50 years of age (Meyers,
McCrory, Nanda, Bastian, & Matchar, 2000). Sexually active young women under 25
are at greatest risk for HPV infection and prevalence of HPV has been shown to be
highest among women aged 20-24 (Dunne et al., 2007). Most HPV infections clear on
their own, but persistent infection with certain types of HPV can cause genital warts,
cervical cancer, or other cancers of the vagina, anus, head, and neck (Huang, 2008).
Over 40 HPV types infect the genital area and types are categorized by their
associated risk to cancer. High-risk types of HPV (specifically 16 and 18) have been
associated with 70% of cervical cancers diagnosed worldwide and low risk-types of
HPV (types 6 and 11) may cause low-grade cervical cell changes and are associated
with 90% of genital warts (Koutsky, 1997).
Two vaccines (GARDASIL® and CERVARIX®) are currently available to
prevent HPV infection in females. In 2006, the Food and Drug Administration (FDA)
approved GARDASIL® (Merck & Co.) for the prevention of cervical cancer, precancerous lesions, and genital warts in females (FDA, 2006). GARDASIL® is a
quadrivalent vaccine (HPV4) protective against HPV types 6, 11, 16, and 18 (Future II
Study Group, 2007). In 2009, the FDA approved CERVARIX® (GlaxoSmithKline)
1

for the prevention of cervical cancer (FDAa, 2009). CERVARIX® (HPV2) is a
bivalent vaccine protective against high-risk HPV types 16 and 18 (Harper, 2008).
The HPV2 and HPV4 vaccines are not live vaccines and both are composed of viruslike particles prepared from L1 capsid proteins (CDC, 2010). Both vaccines have
been demonstrated to be highly protective against oncogenic types 16 and 18 and both
are administered as a three-dose series over six months. HPV4 was also approved as
the only HPV vaccine for use in males aged 9-26 for the prevention of genital warts
and anal cancer (FDA, 2009b; FDA, 2010)
The Advisory Committee on Immunization Practices (ACIP) has
recommended routine vaccination with HPV4 for girls aged 11-12 and catch-up
vaccination for females aged 13-26 since 2007 (Markowitz et al., 2007). Vaccine
should ideally be administered before sexual exposure to HPV, but vaccination is also
recommended for females up to age 26 regardless of previous sexual activity. ACIP
recommendations were updated in 2010 after the approval of HPV2 to extend
recommendation of routine vaccination in these age groups to either HPV4 or HPV2
(CDC, 2010). Updated recommendations also included routine use of HPV4 in males.
Despite ACIP recommendations and new developments in HPV vaccines, uptake of
HPV4 and HPV2 continues to be low among adolescents aged 13-17 recommended
for routine ‘catch-up’ and lower for adult males and females aged 18-26 (CDC, 2011;
CDC, 2012b).
The Centers for Disease Control and Prevention (CDC) provides national
estimates of HPV vaccine coverage annually. CDC monitors national vaccine
2

coverage using two major surveillance systems. The National Immunization Survey –
Teen (NIS) (CDC, 2012c) provides coverage estimates for adolescents aged 13-17 and
the National Health Interview Survey (NHIS) (NCHS, 2012) provides coverage
estimates for adults. The 2011 NIS – Teen results indicated 53% of girls aged 13-17
reported receiving ≥1 dose of the vaccine series and 35% reported receipt of all three
doses (CDC, 2011). CDC further reported that HPV vaccine coverage rates are lower
in younger girls indicating they are not receiving routine vaccination at the
recommended age of 11 or 12. Data are limited for boys, but 8% of boys aged 13-17
had initiated the vaccine series compared to 1% in 2010. Of young adults, the 2010
NHIS found that only 21% of females had received ≥1 dose, up from 17% in 2009.
Less than 1% of males aged 19-26 had received ≥1 dose (CDCb).
Low uptake among males may be partially explained by the fact that they are a
new population recommended for vaccination. Continued low uptake among females
suggests a need to better understand the specific barriers to HPV vaccination,
especially among late adolescent and young adult women at highest risk of infection,
and with lowest coverage of the vaccine. The national target population for HPV
vaccination is girls and boys aged 11 or 12 to complete vaccination before sexual
debut and provide optimal protective benefit. However, vaccinating young adult
women between the ages of 18 and 26 has been shown to contribute to reducing
cervical cancer rates in the population while providing a strong clinical benefit to
individual females, even if they are already sexually active (Harper & Paavonen,
2008; Adams, Jasani, & Fiander, 2009).
3

Previous research has demonstrated that women who have previously been
exposed to HPV would still benefit from vaccination because it is unlikely that they
would have been exposed to all HPV types covered in the vaccine. In a study of 3,276
women aged 19-24, less than 1% were co-infected with both high-risk types 16 and
18, and no women were found to be infected with all four types (Dempsey,
Gebremariam, Koutsky, & Manhart, 2008). Recent research also suggests that HPV
vaccines induce high virus-neutralizing antibodies in young adult women and provides
high protective efficacy comparable to the protective effect in young teenage girls
(Westra et al., 2011). HPV vaccines are prophylactic, not therapeutic, and while only
women negative to vaccine-specific HPV types would optimally benefit from
vaccination, clinical and cost-effectiveness research support comprehensive
vaccination for women up to age 26 (Kim, Orethndahl, & Goldie, 2009). However,
women in this age range are more likely to experience significant barriers to accessing
the vaccine. To increase vaccine uptake among young adult women, further study is
needed to better understand person factors associated with vaccine initiation or nonvaccination among women aged 18 to 26.
More data have become available over the past few years to suggest
demographic, socioeconomic, healthcare, and knowledge characteristics are
significantly related to young adult women receiving the HPV vaccine. Reports from
the NHIS and NIS-Teen surveys indicated differences in vaccine uptake by
demographic and socio-economic characteristics. For example, among adolescents in
the 2011 NIS - Teen, black adolescents were less likely to complete the vaccine series
4

than whites, and completion was lower among adolescents living below the poverty
line (CDC, 2011). However, initiation of the vaccine series was higher among
Hispanics than whites. There are less available data to describe females over 17 years
of age, but the 2010 NHIS reported differences based on ethnicity. Hispanic women
had less coverage than non-Hispanic whites, but no other racial or ethnic differences
were observed (CDCb, 2012). An early study of vaccine uptake reported that vaccine
initiation among women aged 18-26 in the 2007 National Immunization Survey was
positively associated with higher socioeconomic status, not being married, and having
health insurance coverage (Jain et al., 2007). In a university-based clinic system,
vaccine series initiation among young adult women was reported to be negatively
associated with public insurance, white race, and older age (Dempsey, Cohn, Dalton,
& Ruffin, 2011). Socio-demographic factors such as age, race, ethnicity, and
socioeconomic status have also been associated with increased knowledge about HPV
and the HPV vaccine (Ragin et al., 2009) and HPV-related knowledge has been shown
to be another predictor of HPV vaccine initiation among young women (Allen et al.,
2009; Licht et al., 2010). A study examining reasons for non-vaccination among
young women in a large administrative claims database implied improved educational
interventions about HPV and the vaccine may improve uptake. The authors reported
the main reasons for non-vaccination were being married or in a monogamous
relationship, believing the vaccine was too new, concern about side effects, and
uncertainty about insurance coverage and that a physician’s recommendation for
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vaccination resulted in a 4-fold greater likelihood of vaccination (Zimet, Weiss,
Rosenthal, Good, & Vichin, 2010; Rosenthal, Weiss, Zimet, Good, & Vichnin, 2011).
Increasing vaccine initiation among young adult women is a necessary
component of the national HPV vaccination program. Vaccine coverage is low for
most recommended adult vaccines, and far below national targets (CDCb, 2012).
Improvement in vaccine uptake among adults is needed to reduce morbidity and
mortality of vaccine-preventable diseases such as HPV. More research to better
describe and understand this distinct group of women and their personal reasons for
non-vaccination would benefit targeted interventions for young adult women. The
objectives of this study were to describe women aged 18-26 in a recent national
sample who report non-vaccination against HPV, determine predictors of HPV nonvaccination, and identify a minimum subset of variables to develop a predictive model
of non-vaccination.

6

METHOD

Design Overview and Sample Selection
National Health Interview Survey
This study used data collected by the 2010 National Health Interview Surveys
(NHIS) to develop a prediction model, and then used data from the 2011 NHIS to
examine the robustness of significant multivariate-adjusted predictors an independent
sample. The National Health Interview Survey (NHIS) is a primary source of
information on the health of the civilian non-institutionalized population of the United
States. It is considered a major data collection program of the National Center for
Health Statistics (Centers for Disease Control and Prevention) and used by the
Department of Health and Human Services to monitor health trends, track progress
towards reaching national health objectives, and provide national estimates. Due to
the collection of many demographic and socio-economic variables, NHIS data are
frequently used by public health researchers for epidemiological studies to identify
and describe groups at higher risk for certain health conditions and to examine barriers
to health care access and utilization. More information about the National Health
Interview Surveys is available here: http://www.cdc.gov/nchs/nhis.htm.
NHIS Sampling Design
NHIS is a cross-sectional interview survey conducted annually among a
nationally representative sample of households. NHIS uses a stratified, multistage,
cluster sampling design. Black, Hispanic, and Asian persons are intentionally
7

oversampled to ensure adequate representation in the sample. Institutionalized
individuals are excluded; examples of these individuals include patients in long-term
care facilities, persons on active duty with the Armed Forces, and incarcerated
persons. Basic person weights are used to analyze person record data and person
weights are adjusted to Census control totals for sex, age, and race/ethnicity
populations. NHIS data are for public use and the data sets, documentation, survey
instruments, and sample statements for various statistical software packages are
available for download online.
Data collection is continuous through the year and a probability sample of the
US non-institutionalized population is interviewed each week. Face-to-face
interviews are conducted by personnel from the U.S. Bureau of Census using
computer-assisted personal interviewing. One adult from each household is randomly
selected to self-report responses for the Sample Adult File. For the Family File, all
household members 17 years of age or older are invited to participate and respond for
themselves; a responsible adult household member (18 years or older) is allowed to
provide responses for children and other adults not present at the time of interview.
The questionnaire contains the “core” questionnaire which includes three components
(Family, Sample Adult, and Sample Child) to cover a broad range of health and
demographic items, including vaccine coverage. A “supplement” questionnaire may
be included in some years of the NHIS to monitor current health issues. The core
questionnaire consistently includes questions specific to vaccination [e.g. Hepatitis A
and B, Influenza, pneumococcal polysaccharides vaccine (PPV), Herpes Zoster,
8

Tetanus-Diphtheria-Pertussis (Tdap)] to inform national coverage estimates. In 2008,
new questions were added to the NHIS to assess vaccine coverage related to the recent
approval and ACIP recommendations for HPV vaccination. In 2010, an Adult Cancer
File Supplement was included as the yearly supplement to examine adult cancers
including cervical cancer. This file includes additional questions specific to cervical
screening history, HPV vaccination history, attitudes about HPV vaccination, and
reasons for non-vaccination.
Design Overview and Sample Selection
Initial analyses were based on 27,157 adults (18 years or older) from the 2010
Adult Cancer File. The sample for analysis was restricted to a subset of late
adolescent women aged 18-26 (N=1,866) who reported yes or no to the survey
question, “ever received the HPV shot or vaccine?” The Adult Cancer Files was then
merged with the Person and Adult Files to obtain additional-level demographic and
health information. All data used for analysis was obtained from public-use data files
made available by the National Center for Health Statistics. All personally-identifying
information is removed from the data files prior to data release. This study met
exemption criteria for oversight by the University of Rhode Island Institutional
Review Board.
Measures
The dichotomous outcome variable was initiation of the HPV vaccine series
defined as receipt of ≥1 doses of the HPV vaccine. HPV vaccine initiation is defined
by the NHIS variable name SHTHPV1 (“ever received the HPV shot or vaccine”).
9

Since the outcome of interest was non-initiation of vaccination, a response of no was
coded as 1 (n=1,458; 72.50%) and a response of yes was coded as 0 (n=408; 20.29%).
All other responses including doctor refused when asked (n=1; 0.05%), refused (n=7;
0.35%), not ascertained (n=119; 5.9%) and don’t know (n=18; 0.90%) were excluded
from the analysis.
The predictor variables were derived from the Adult, Person, or Adult Cancer
Files. The predictor variables of interest were selected based on previous research
describing factors associated with HPV vaccine receipt. The data dictionary (variable
summary and frequency reports of the Adult Cancer, Person, and Adult Files) were
then scanned to match factors related to variables in the questionnaire. The 2010
NHIS Survey Description document was also consulted for analytic recommendations
regarding variable recodes and assessment of commonly used variables such as public
health insurance and income (NCHS, 2010). The large number of predictor variables
selected for analysis were grouped into four domains to establish an organizing
framework for the study: 1) demographic, 2) socioeconomic, 3) health services
utilization, and 4) HPV awareness.
Thirty-nine variables were identified for exploratory analysis and grouped into
categories. Variables and their original response categories are presented in Table 1.
The goal of this exploratory analysis was to examine the characteristics of each
variable, determine if the variable could potentially be used in a modeling analysis,
and, if necessary, prepare potential variables for bivariate tests of association. Means
and frequencies of each variable were examined and then crosstabs between the
10

potential predictor and the outcome variable were conducted to examine cell size. To
ensure reliable estimates, variables were required to contain 30 or more observations
per cell (NCHS, 2010). Variables with small cell counts were then manipulated to
facilitate statistical analyses. For example, categorical variables with multiple levels
may have been collapsed to increase cell counts and examine the relationship between
predictor and outcome.
Initial demographic variables included age (categorized to 18-21, 22-25, and
26), race recoded (recoded to white, non-white), ethnicity (Hispanic, not Hispanic),
marital status (recoded to married, not married), primary language (recoded to
English, non-English), born in US (yes, no), US census region (South, Northeast,
Midwest, and West), and given birth in the past 5 years (yes, no). Assessment of
parametric form was conducted for the continuous variable of age (Hosmer &
Lemeshow, 2000). To examine the association of age to vaccine receipt, age was
categorized into 1 year intervals from 18-26 using 18 as the reference group and then
plotted against the log odds of vaccine initiation. The plot demonstrated a nonlinear
relationship and suggested three previously specified levels for age (18-21, 22-25, and
26).
Socioeconomic variables included no insurance coverage (yes, no), private
insurance coverage (yes, no), public insurance coverage (yes, no) including Medicare,
Medicaid, and other state or government plans as described in the 2010 NHIS Survey
Description, education (recoded to college education yes or no), and income (recoded
to <$20,000, $20,000-$34,999, and >$35,000). College education was also examined
11

as a multilevel categorical predictor with four levels: less than high school, high
school, some college, college or higher.
Health utilization variables included ever receiving a Pap test (yes, no),
abnormal Pap test results (yes, no), HPV diagnosis (yes, no), reported health status
(recoded to excellent/very good, good/fair/poor), has usual place of care (yes, no),
place to go when sick (recoded to doctor’s office or clinic, other), seen/talked to a
doctor in past 12 months (yes, no), seen/talked to an OB/GYN in past 12 months (yes,
no), currently using birth control (yes, no), receipt of flu shot in the past 12 months
(yes, no), receipt of Hepatitis A vaccine (yes, no), receipt of Hepatitis B vaccine (yes,
no), receipt of tetanus shot in the past 10 years (yes, no), had an STD test in past 5
years (yes, no), saw a doctor for an STD (yes, no), and ever been tested for HIV (yes,
no).
HPV-related knowledge variables included ever heard of HPV (yes, no) and
ever heard of the HPV vaccine (yes, no). Other HPV-related attitudes and awareness
items included in the 2010 Adult Cancer Supplement that were exclusive to women
who did not initiate vaccination were examined for descriptive purposes (e.g. interest
in the HPV vaccine, reasons for non-vaccination, and willingness to get the vaccine at
lower cost).
Statistical Analyses
Step 1: Variable Selection
The goal of this analysis was to identify the variables significantly associated
with HPV vaccine initiation in simple bivariate analyses, and retain these variables for
12

model development. Associations between the outcome and each predictor variable
were examined using t tests for continuous variables or chi-square tests of
independence for categorical variables. Variables were retained for further analysis if
associations were significant at the p<.20 level based on the Wald chi-square statistic,
provided more than 30 observations per cell, or if they are supported through theory or
empirical research. The 0.20 level was chosen as a screening criterion for variable
selection rather than the traditional 0.05 level because this cut-off may fail to identify
variables that would be important when combined in a multivariate model (Hosmer &
Lemeshow, 2000).
Step 2: Unadjusted Odds Ratios
Variables that were retained based on bivariate associations were examined
further to assess the strength of their relationship to the outcome. Univariate logistic
regressions, unadjusted odds ratios, and 95% confidence intervals were calculated for
each predictor. Variables significant at the traditional p<.05 with standard error of the
prevalence estimate <30% were considered to be strong predictors and selected for
retention in further modeling analyses (NCHS, 2006). At this stage, collinearity
diagnostics in each group were reviewed. Variables with a condition index over 30,
with a variance inflation factor (VIF) over 10, or pairs that explain more than 50% of
the variance were to be dropped from the analysis (Menard, 1995). Finally, potential
interaction terms between significant variables in each variable grouping were
examined. Interaction terms were evaluated to ensure they satisfied the hierarchy
principle recommended by Kleinbaum and Klein (Kleinbaum & Klein, 2002). The
13

hierarchy principle states that all lower-order components of the model must be
retained if there is a significant higher-order interaction term. In other words, it
would be inappropriate to remove a main effects variable from the model if the model
contains an interaction term involving that variable.
Step 3: Separate Multivariable Logistic Regression Models
Variables that met criteria for retention in the last step were entered into four
separate multiple logistic regression models based on groups. This approach allows
related significant variables to compete with each other to identify the strongest
predictors, thereby facilitating the selection of a minimum subset of variables to
predict the outcome (Snyder, Willey, McKenna, Foley & Coleman, 2005). Variables
from the group-specific models that were significant at the p<.05 level were retained
for inclusion in the final model.
Step 4: Final Model
The retained predictors were tested in a final model to identify the most
parsimonious equation to predict HPV non-vaccination. After the main effects were
identified, interaction effects were examined. The results of the modeling approach
were confirmed by backwards selection procedure. Multivariate-adjusted variables
significant at the p<.05 level were considered final predictors and the model was
judged to fit the data by a nonsignificant Hosmer-Lemeshow goodness of fit test at the
0.05 level of significance, and by the C-statistic. Values for the C-statistic range from
0.5 to 1.0 and a value of 0.5 indicates the model is no better than chance at predicting
group membership. Typically, values higher than 0.7 indicate acceptable
14

discrimination, values higher than 0.8 indicate excellent discrimination, and values
higher than 0.9 indicate outstanding discrimination (Hosmer & Lemeshow, 2000).
Area under the curve, sensitivity, specificity, and max rescaled R-square were also
presented to display the predictive power of the logistic model. After the model was
specified, its predictive capacity was tested by testing the model in the 2011 NHIS
dataset as a confirmatory analysis.
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RESULTS

Sample Characteristics
Of women aged 18-26 in this sample, 78.1% (n=1,458) did not initiate HPV
vaccination. Summary characteristics of non-vaccinated women including select
demographics, socioeconomic, and health utilization variables are presented in Table
2. Mean age was 22.6 years (SD=2.4). The majority were white (49.6%), unmarried
(78.2%), had health insurance (75.4%), and had at least some college education
(57.5%).
Reasons for non-vaccination, vaccine awareness, and other HPV-vaccine
related attitudes are presented in Table 3. Reasons to not initiate vaccination varied.
Of unvaccinated women, 34.6% reported they had not heard of the HPV vaccine and
62.9% reported they were not interested in receiving it. The three main reasons for not
receiving the vaccine were “does not need vaccine” (40.4%), “don’t know enough
about the vaccine” (13.5%), and “worried about safety of the vaccine” (10.8%).
Summary characteristics of the other women who received at least one dose of the
vaccine series (n=408) are presented in Table 4.
Bivariate Results
Table 5 summarizes the results of preliminary statistical tests to screen a large
number of potential predictor variables. Most items that were related to
demographics, socioeconomic, and health services utilization were significantly
associated with vaccine initiation. Nine variables (full-time work, previous STD test,
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ever heard of HPV vaccine, five health insurance variables related to public insurance,
and one item related to insurance ineligibility) could not be examined statistically
because of small counts. Variables that met established criteria for retention (e.g.
significant univariate odds ratios) were examined in category-specific logistic
regression models.
Model 1: Demographics Variables
Age, region, race, ethnicity, primary language, marital status, born in the US,
and live birth in the past 5 years were all significant independent predictors of vaccine
initiation. Age, region, marital status, and live birth in the past 5 years remained
statistically significant when adjusted for other variables. Table 6 presents the
unadjusted and adjusted odds ratios and 95% confidence levels. In multivariate
analyses, older age, 22-25 years (aOR=2.30, 95% CI=1.79, 2.95) and 26 years
(aOR=1.83, 95% CI=1.25, 2.69), being married (aOR=1.49, 95% CI=1.04, 2.14), and
having had a live birth in the past 5 years (aOR=1.81, 95% CI=1.36, 2.40) were
associated with higher odds, or increased risk, of non-vaccination. Living in the
Midwest (aOR=0.73, 95% CI=0.54, 0.99) or West (aOR=0.67, 95% CI=0.49, 0.90)
was associated with lower odds of being in the non-vaccinated group. Potential
interactions were assessed at the univariate level, and then adjusted for multivariate
analyses. At the univariate level, there were significant interactions between race and
age of 22-25 years (p<.0001), race and age of 26 years (p=.03), marital status and age
of 22-25 years (p<.0001), live birth and age of 22 and 25 years (p<.0001), live birth
and age of 26 years (p=.007), live birth and marital status (p<.0001), live birth and
17

race (p<.0001), race and Midwest (p=.02), and race and West (p=.04). No interaction
terms remained significant in the multivariate model. Multicollinearity was also
assessed and no multicollinearity was detected at this level. The model fit the data
well as evidenced by a nonsignificant Hosmer and Lemeshow goodness of fit test (chisquare=1.55, Pr>chi-square=0.67).
Model 2: Socioeconomic Variables
In univariate analyses, no insurance coverage, private insurance coverage,
Medicaid coverage, and college education were significant independent predictors of
vaccine initiation. College education and no insurance coverage remained statistically
significant multivariate-adjusted predictors when entered into the category-specific
model. Table 7 presents the unadjusted and adjusted odds ratios and 95% confidence
intervals. In multivariate analyses, no insurance coverage (aOR=1.86, 95% CI=1.16,
3.00) was associated with increased risk of non-vaccination, while having a college
education (aOR=0.74, 95% CI=0.75, 0.95) was associated with decreased risk of being
non-vaccinated. Education and insurance coverage showed a significant interaction at
the univariate level (p=.01), but it was not demonstrated to be significant at the
multivariate level. Multicollinearity diagnostic procedures were also conducted and
no multicollinearity between variables was detected. The model fit the data well as
evidenced by a nonsignificant Hosmer and Lemeshow goodness of fit test (chisquare=1.48, Pr>chi-square=.82).
Model 3: Health Services Utilization Variables
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In univariate analyses, tetanus shot in the past 10 years, Hepatitis A vaccine,
Hepatitis B vaccine, flu shot in the past year, current birth control use, having been
diagnosed with HPV, doctor’s visit within the past 12 months, and having a usual
place of care were all significant independent predictors of non-vaccination. Tetanus
shot, flu shot, current birth control use, doctor’s visit in the past year, and usual place
of care remained statistically significant in multivariate analysis. Unadjusted and
adjusted odds ratios with 95% confidence intervals are presented in Table 8.
Multivariate results indicated that tetanus shot (aOR=0.45, 95% CI=0.27, 0.75), flu
shot (aOR=0.52, 95% CI=0.34, 0.78), current birth control use (aOR=0.47, 95%
CI=0.32, 0.69), doctor’s visit in past year (aOR=0.56, 95% CI=0.32, 0.69), and usual
place of care (aOR=0.51, 95% CI=0.28, 0.94) were associated with decreased odds of
being non-vaccinated. Significant interactions at the univariate level were found
between tetanus shot and flu shot (p<.0001), usual place of care and doctor’s visit in
the past year (p<.0001), and birth control pills and doctor’s visit in the past year
(p<.0001). No interaction terms were determined to be multivariate-adjusted
predictors and no multicollinearity was detected in this category. The model fit the
data well as evidenced by a nonsignificant Hosmer and Lemeshow goodness of fit test
(chi-square=12.32, Pr>chi-square=0.13).
Model 4: HPV Awareness
Two variables were initially examined for this model. The variable “heard of
HPV vaccine” was eliminated due to small cell count (Table 9). Having heard of HPV
was associated with decreased odds of being in the non-vaccinated group (OR=0.24,
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95% CI=0.16, 0.35), but was not chosen for inclusion in the final model due to
potential error (e.g. women who report HPV vaccination, but have not heard of HPV).
Final Model
Significant variables identified in category-specific logistic models were
entered into one final model. The nonsignificant variables from the category-specific
models were deleted to achieve the aim of specifying the most parsimonious model
able to predict non-vaccination. Eleven variables included in the preliminary model
included age, no insurance coverage, marital status, college education, usual place of
care, live birth in the past 5 years, birth control, doctor’s visit in past year, flu shot in
the past year, and tetanus shot in past 10 years (Table 10). In multivariate analysis, no
insurance coverage, college education, and usual place of care did not remain
statistically significant. To confirm this approach, a backwards selection procedure
was conducted and results supported the deletion of usual place of care and college
education, but supported the retention of insurance coverage in the model. To address
the discordance in results, two models were specified and compared using the
likelihood ratio test (Kleinbaum & Klein, 2002). Both models excluded college
education and usual place of care, but the first model excluded no insurance coverage,
and the second model included no insurance coverage. Results of the likelihood ratio
test indicated the first model that excluded insurance coverage fit the data better
(deviance difference 1026.69-1025.04=1.65, DF difference 12-11=1, χ2(1)=3.84).
Since the deviance difference is less than the chi-square critical value, the model with
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more parameters is not an improvement over the partial model. Both models are
presented here.
The first model was developed according to the model-building approach
described previously, and without the variable of insurance coverage. This model
included eight significant multivariate-adjusted predictors of non-vaccination (Table
11). Variables significantly associated with increased odds of non-vaccination
included older age (22-25 years compared to 18-22 years) (aOR=2.93, 95% CI=2.00,
4.30), being married (aOR=1.75, 95% CI=1.02, 3.01) and having a live birth in the
past 5 years (aOR=2.77, 95% CI=1.75, 4.39). Variables significantly associated with
decreased odds of being in the non-vaccination group included living in the West as
compared to the South (aOR=0.50, 95% CI=0.31, 0.79), currently being on birth
control (aOR=0.45, 95% CI=0.31, 0.64), flu shot receipt in past year (aOR=0.36, 95%
CI=0.24, 0.54), tetanus shot in the past 10 years (aOR=0.41, 95% CI=0.26, 0.62), and
seeing a doctor in the past year (aOR=0.57, 95% CI=0.39, 0.84). Multiple potential
interaction terms were assessed. Five interaction terms were significant at the
univariate level: 22-25 years of age and live birth (p<.0001), 22-25 years of age and
marital status (p<.0001), 22-25 years of age and Northeast (p=.002), 22-25 years of
age and West (p=.003), marital status and live birth (p<.0001). No interaction terms
were significant as multivariate-adjusted predictors. No multicollinearity was detected
(Table 12). This model showed good fit to the data as evidenced by a nonsignificant
Hosmer & Lemeshow goodness of fit test (chi-square=14.41(8); Pr>chi-square=.07)
and a significant model chi-square of 193.30(11); Pr>chi-square=<.0001. The c21

statistic was 0.795 indicating a strong prediction capacity. Max rescaled R-square was
0.268. Area under the curve is presented in Figure 2 and classification tables are
presented in Table 13.
The second model included insurance coverage based on the backwards
selection procedure results (Table 14). This model included nine significant
multivariate-adjusted predictors of non-vaccination. Variables associated with
increased odds of non-vaccination included older age (22-25 years compared to 18-22
years) (aOR=2.91, 95% CI=1.99, 4.27), being married (aOR=1.81, 95% CI=1.06,
3.17), having a live birth in the past 5 years (aOR=2.67, 95% CI=1.69, 4.23), and not
having insurance coverage (aOR=1.70, 95% CI=1.06, 2.72). Variables associated
with protection against being in the non-vaccination group included living in the West
(as compared to South) (aOR=0.49, 95% CI=0.31, 0.78), currently being on birth
control (aOR=0.46, 95% CI=0.32, 0.66), flu shot receipt in past year (aOR=0.36, 95%
CI=0.24, 0.54), tetanus shot in the past 10 years (aOR=0.42, 95% CI=0.27, 0.66), and
seeing a doctor in the past year (aOR=0.63, 95% CI=0.43, 0.93). Six interaction terms
were significant at the univariate level: 22-25 years of age and live birth (p<.0001),
22-25 years of age and marital status (p<.0001), 22-25 years of age and Northeast
(p=.002), 22-25 years of age and West (p=.003), no insurance coverage and Midwest
(p=.003), and marital status and live birth (p<.0001). No interaction terms were
significant as multivariate-adjusted predictors. Multicollinearity was assessed and no
multicollinearity was detected (Table 15). This model showed also good fit to the data
as evidenced by a nonsignificant Hosmer & Lemeshow goodness of fit test (chi22

square=10.24(8); Pr>chi-square=.24) and a significant model chi-square of
198.05(12); Pr>chi-square=<.0001. The c-statistic was 0.797 indicating a strong
prediction capacity (Hosmer & Lemeshow, 2000). Max rescaled R-square was 0.27.
Area under the curve is presented in Figure 3 and classification tables are presented in
Table 16.
Cross-Validation Model: 2011 National Health Interview Survey
To further examine the robustness of the significant predictors in final model,
these predictors were tested in an independent sample using a reduced set of variables.
The 2011 National Health Interview Survey is structured to allow analysis across
multiple years. Six of the eight significant multivariate-adjusted predictors from the
final model were included in the 2011 person-level files; live birth in the past 5 years
and current birth control use were exclusive to the 2010 Adult Cancer File Supplement
and not available for 2011-level analysis. Parametric assessment for age was assessed
and revealed a non-linear pattern with three distinct age groups (18-24, 25, and 26). In
2011, 71.5% (n=1,655) women reported not receiving the HPV vaccine and 28.4%
(n=659) reported receipt of ≥1 dose. Five variables were significant multivariateadjusted predictors of non-vaccination (Table 17); region was the only variable that
was not strictly statistically-significant when adjusted for other variables, but one-level
(West) was borderline significant (p=.05). Variables that showed increased risk of
non-vaccination included age (25 years) (aOR=1.61, 95% CI=1.19, 2.19) and age (26
years) (aOR=2.42, 95% CI=1.70, 3.43), and marital status (aOR=2.38, 95% CI=1.78,
3.19). Variables protective against non-vaccination included receipt of flu vaccine in
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past year (aOR=0.60, 95% CI=0.49, 0.75), receipt of tetanus shot in past 10 years
(aOR=0.46, 95% CI=0.36, 0.57), and seeing a doctor within the past year (aOR=0.62,
95% CI=0.51, 0.77). Multicollinearity was assessed using the procedure described
previously and no multicollinearity was detected (Table 18). This model showed a
good fit to the data as evidenced by a nonsignificant Hosmer-Lemeshow goodness of
fit (chi-square=2.80(8); Pr>chi-square=.94), a c-statistic of .696, and a max re-scaled
R-square of .13. Area under the curve is presented in Figure 5 and classification tables
are presented in Table 19.
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DISCUSSION

Seven years after the approval of the first HPV vaccine, US women aged 18-26
continue to have lower HPV vaccine coverage compared to adolescent girls. The goal
of this study was to describe US women who have not initiated the vaccine series,
examine their reasons for non-vaccination, and identify predictors of non-vaccination.
We found that 78% of women recommended for routine vaccination did not receive
the vaccine, and 35% of unvaccinated women had not ever heard of the vaccine.
Current findings indicate that non-vaccinated women differed from vaccinated women
on several key socio-demographic and healthcare utilization variables. Women who
were older, married, and had children were at higher risk for being unvaccinated,
while women who lived in the West, had a recent doctor’s visit, and practiced
preventative health behaviors such as using birth control, receiving a yearly flu
vaccine, or recent tetanus vaccine were more likely to be vaccinated. These findings
suggest that there are subgroups of 18-26 year old women at higher risk for nonvaccination, and findings may inform targeted interventions to increase vaccine
delivery to these subgroups.
In our study, older age was the strongest predictor of non-vaccination status.
Being 22-25 years old was associated with a nearly three-fold increase in the odds of
being unvaccinated compared to being 18-21 years old. Previous research examining
HPV vaccine uptake in young adult women has reliably demonstrated younger age to
be strongly associated with vaccine initiation (Licht, 2010; Dempsey, 2011; Chao,
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Velicer, Slezak & Jacobsen, 2010; Rosenthal, 2011; Tiro et al., 2012; Marchard,
Glenn, & Bastani, 2013). Younger age may be a protective factor against nonvaccination due to the increased likelihood that younger women have access to health
care and may still qualify for “safety net” vaccine delivery programs such as the
Vaccine For Children (VFC) program (Marchard, 2013; Dempsey 2008). The VFC
program provides free vaccines, including HPV vaccines, to low-income, uninsured
children and adolescents aged 18 years or younger. Younger women are also more
likely to be enrolled as full-time college students and are generally required to be
covered under their college health plan or parental health insurance. Increased vaccine
coverage of college-aged women may be associated with receipt of other vaccinations
due to pre-matriculation vaccine requirements, parental influence, and access to the
HPV vaccine through college health centers (Licht, 2010).
Women outside of college, or uninsured older women, can face significant
financial barriers to accessing the vaccine. Of unvaccinated women in our sample
who were asked if they would receive the vaccine if it was free or lower cost, 96%
said yes. HPV vaccines are the most expensive vaccines to date with retail costs
averaging about $130 per dose ($390 for full series) (CDC, 2012d). It has been
previously demonstrated that young adults aged 18-26 in the US are at high-risk for
being uninsured (or under-insured to cover vaccines) when they reach the age where
they cease to be covered under parental insurance, and have not yet established their
own work-based health insurance (Park, Mulye, Adams, Brindis, & Irwin, 2007;
Nicholson et al., 2009). In our study, not having health insurance was a significant
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univariate predictor of non-vaccination, though it dropped out of the final model.
Further exploration of this variable is warranted. Findings from other national
probability samples have indicated insurance coverage to be a univariate and
multivariate-adjusted predictor of vaccination. An early 2007 analysis of adult women
in the National Immunization Survey (Jain, 2007) indicated that insurance coverage
was positively associated with vaccine uptake and a 2010 analysis of the National
Family Growth Survey found insurance coverage to be significantly associated with
vaccine initiation regardless of age (Liddon, Leichliter, & Markowitz, 2012). Further
examination of current vaccine assistance programs for uninsured young people is
needed to examine how these programs can better respond to national vaccine needs
and gaps. Marchand et al. (2012) suggest catch-up vaccination rates among uninsured,
low-income women may be increased by revising age inclusion criteria for adolescent
vaccine safety-net programs to consider young adults up to age 26, as well as
encouraging community health centers to participate in manufacturer-based cost
assistance programs (Merck’s Patient Assistance Program and GlaxoSmithKline’s
Cervarix program).
In addition to age, we found demographic variables such as marital status and
having children to be significant risk factors for non-vaccination. Married women
were 84% more likely to be unvaccinated compared to unmarried women; women
who had children were more than twice as likely to be unvaccinated compared to
women without children. These findings may reflect a belief among women, and
potentially among their providers, that they are not at risk for HPV or would not
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benefit from vaccination. In a 2010 study of young women’s reasons for nonvaccination, the authors found that 55% of women reported they did not initiate
vaccination because they were married or in a monogamous relationship (Zimet,
2010). A perceived lack of need due to perceived low risk (e.g. being in a committed
relationship, few or no sexual partners) has been shown to be a predictor of nonvaccination in other population surveys (Grant, Kravitz-Wirtz, Breen, Tiro, & Tsui,
2009; Jain, 2007). We also found that 63% of unvaccinated women reported they
were not interested in receiving the vaccine. When asked about their main reason for
not receiving the vaccine, 44% of women reported reason they did not need it. Despite
evidence to support universal vaccine recommendations for this age group, some
women may incorrectly think they do not need the vaccine because they are low risk,
already infected with HPV, or too old to receive any protective benefit. Routine use of
the HPV vaccine in catch-up women, even if they were already sexually active, was
recommended over a targeted risk-factor approach due to the ubiquitous nature of
HPV infection and data showing that it is unlikely that women exposed to one type of
HPV have been exposed to all types covered in the vaccine. Thus, older women can
obtain partial clinical benefit from vaccination after sexual debut, or after exposure to
HPV. Misconceptions regarding vulnerability to HPV disease and HPV vaccine
efficacy reflect important gaps in young women’s HPV-related knowledge, and efforts
to increase vaccine uptake would benefit from information-driven campaigns that aim
to correct key observed misperceptions. While general knowledge about HPV, the
association between HPV and cervical cancer, and the availability of a preventive
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vaccine is high among young women, more complex information about HPV
transmission, screening, other disease consequences have been demonstrated to be low
in samples of young women (Allen, 2009; Licht et al., 2010; Lopez & McMahan,
2007; Sandfort & Pleasant, 2009; Gerend & Magloire, 2008). Knowledge-based
campaigns may benefit from providing additional clinical information about HPV
transmission, HPV disease, and prevention to inform more accurate risk perceptions
for HPV.
Additionally, disagreements among national leaders about vaccine
recommendations for 18-26 year old women can contribute to public confusion or
misperceptions of vaccine benefit. While ACIP recommends universal vaccination,
the American Cancer Society (ACS) cites insufficient evidence to recommend
vaccination in all 19-26 year old females (Saslow et al., 2007). ACS instead suggests
providers base their decision to vaccinate on the patient’s individual risk factors for
previous HPV exposure and number of sexual partners. Conflicting national
guidelines reflect discordant opinions among health care providers about the public
health and clinical benefits of vaccination for women who are already sexually active.
Unvaccinated women are likely to be influenced by their providers’ opinions when
making decisions about vaccination (Brewer & Fazekas, 2007; Hopfer & Clippard,
2011). A 2010 study of insured women aged 19-26 showed that women who received
a physician’s recommendation for vaccination were more likely to be vaccinated
(Rosenthal, 2010); further, a strong recommendation resulted in a 4-fold greater
likelihood of vaccination than one that was not strong. It is has been shown that
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physicians who disagree that the vaccine can provide protective benefit to an older
female do not recommend HPV vaccination and advise against it (Goff, Mazor,
Schaffer, Corey, & Blake, 2011). In our sample, 7% of women indicated their main
reason for not receiving the vaccine was because their doctor did not recommend it.
Zimet et al. (2010) found that 5% of 18-26 women did not initiate vaccination because
their doctor recommended against it. Further research is needed to examine the
proportion of physicians who do not support adult HPV vaccination, or do not
recommend it to their patients for other reasons.
In addition to multiple risk factors for non-vaccination status, we also found
several factors to be protective against non-vaccination. First, US census region of
residence was found to have a protective effect against non-vaccination. In univariate
analyses, living in the Midwest or West was associated with increased odds of
vaccination compared to those living in the South, but in multivariate analyses only
living in the West was associated with increased odds of vaccination. Recent research
specific to geographic variability in HPV vaccine uptake has also demonstrated that
18-26 year olds in the Midwest and West regions were more likely to be vaccinated
than young women in the Northeast (Wei, Moore, & Green, 2013). The authors
believed geographic variability may be influenced by regional providers’ likelihood of
recommending vaccine and by women’s knowledge and attitudes regarding HPV and
HPV vaccines. There is little other research to explain geographic variability, but a
2010 study from CDC revealed HPV vaccine coverage to be lower among adolescent
girls living in the Southeastern US compared to girls living in other regions (CDC,
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2011b). Further, areas with higher poverty rates may explain geographic variability;
among girls in six US states, girls living in higher-poverty states were shown to be less
likely to be vaccinated (Pruitt & Schootman, 2010).
Healthcare utilization, or more specifically, health prevention behaviors, such
as having had a doctor’s visit in the past year, current birth control, flu vaccine receipt,
and tetanus vaccine receipt were also found to be protective factors. In a recent
review of HPV vaccine uptake among adolescent women, a study showed that 43% of
adolescents who received HPV vaccine also received a second preventative health
service (Etter, Zimet, & Rickert, 2012). In univariate analyses in our study, having a
usual place of care, or medical home, was a significant predictor of vaccine initiation.
It is reasonable to assume that vaccinated, insured women with recent health care
visits are engaging in other health care prevention behaviors such as pregnancy
prevention and adherence to other recommended vaccines.
Among the significant healthcare utilization predictors, receipt of flu vaccine
in the past year was found to be the most protective factor. Women who received a flu
vaccine were almost three times as likely to have initiated the HPV vaccine series.
Receipt of other vaccines has been shown to predict HPV vaccination behavior in
other national probability samples. For example, Jain et al., (2007) found that young
women who were vaccinated against Hepatitis B were more likely to have received at
least one dose of the HPV vaccine series. Receipt of flu vaccine has also been shown
to influence uptake of other vaccines such as Tdap (Miller, Kretsinger, Euler, Lu, &
Ahmed, 2011). Women who report receipt of multiple recommended vaccines may
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have more confidence in vaccine safety and efficacy. Further research is needed to
better understand the variables that predict public confidence in vaccines. Among
unvaccinated women in this sample, concerns about not knowing enough about the
vaccine and concerns about the safety of the vaccine emerged as the second and third
most frequently reported reasons for non-vaccination. These results reflect previous
findings from young women who cited concerns about lack of sufficient information
about the vaccine, and concerns about side-effects or the vaccine being too new
(Zimet, 2010). Addressing lack of public confidence in vaccines is emerging as a
research priority to identify new interventions to increase vaccine coverage (Larson,
Cooper, Eskola, Katz, & Ratzan, 2011). Health communications campaigns may
benefit from acknowledging lack of public confidence in vaccines, and working with
target populations to develop vaccine messages that build public trust in vaccines.
New messages are needed that communicate the excellent safety and efficacy record
of both vaccines, while providing accurate information about risk-benefit ratio of
vaccines. Campaigns should direct unvaccinated individuals to objective (nonindustry) sources of vaccine safety information (such as the CDC or other trusted
entity) so individuals are confident in their ability to make informed decisions about
their personal risks and benefits of vaccination.
Limitations
The current study has several limitations. First, results are based on one crosssectional analysis and further examination of findings to predict non-vaccination will
require longitudinal designs. Second, NHIS relies exclusively on self-report measures
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and is not confirmed by objective measures. All self-report data are vulnerable to
recall and misclassification bias and caution should be used when interpreting rates of
vaccination and other data. Third, the NHIS was restricted to noninstitutionalized
civilian adults and generalization to the wider population cannot be inferred.
Oversampling of ethnic and racial minority groups may inflate estimates relating to
these groups. Additionally, there is potential coverage bias or bias that exists for the
exclusion of households without landline telephones (Blumberg & Luke, 2012). For
example, in comparative analyses between people with landline phone only and
people with wireless phones only, wireless people tended to be older, in poverty,
living in the Midwest, South, or West as compared to the Northeast, and Hispanic or
Black. Fifth, multivariate models required complete data on all variables used in the
model and this reduced sample size, thereby potentially reducing the statistical power
of the model. Lastly, estimates were not weighted in SUDAAN to account for the
complex sampling design.
Implications
Current findings contribute to previous research demonstrating disparities in
vaccine uptake among 18-26 year old women. While vaccine uptake in this age group
has increased since 2007, young adults lag far behind adolescent girls aged 11-17 and
it is unlikely optimal vaccine coverage targets will be met among this group unless
evidence-based targeted programs are designed and implemented to address the
variables known to predict non-vaccination. Significant challenges exist in developing
effective, scalable interventions to reach high-risk subgroups of adult women. Many
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variables significant in multivariate analyses can be considered “static” and not
amenable to intervention. Infrastructure and funding for adult vaccine uptake are
lacking to adequately address structural barriers to vaccination, but vaccine promotion
programs may benefit from further examination specific to HPV and HPV vaccine
knowledge and attitudes, personal reasons for not receiving vaccination, and general
public confidence in vaccines. In the US, adult vaccine coverage (adults ≥19 years of
age) of recommended vaccines continues to be low, and lower than objectives set for
Healthy People 2020. In addition to general public health practice recommendations
of increased access to vaccines through non-traditional venues (e.g. pharmacies,
workplaces, and community events), clinic reminder systems, and reduced financial
barriers, programs of research to increase vaccine uptake may also benefit from
interventions that aim to increase physician recommendation for vaccination, increase
perceived risk for HPV without vaccine, increase perceived benefit of the vaccine,
and decrease inflated concerns about safety and side-effects.
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Table 1. All Potential Predictors and Original Response Categories

Race Recode
Race/Ethnicity
Hispanic Ethnicity
Marital Status
Born in US
Language
Region
Age
Live birth within past 5 years
Medicaid
Medicare
State Children’s Health
Insurance Program coverage
State-sponsored health plan
Other government health
plan
Military health care
coverage
Ineligible because of
age/school
Private Insurance
No Coverage
Education

Total earnings last year

Full time work
Pap test ever
Abnormal Pap test results past 3 years
Told by doctor had HPV
Reported Health Status
Has usual Place to go when
sick

White only, Black only, American Indian/Alaskan Native only,
Asian only, Multiple Race, Not Released
Hispanic, White, Non- Hispanic Black, Other
Yes, No
Separated, Divorced, Married, Single/Never Married, Widowed,
Unknown
Yes, No, Refused, Don't Know
Only Spanish, Mostly Spanish, Spanish and English, Mostly
English, Only English, Other, Not Ascertained
Northeast, Midwest, South, West
Continous
Yes, No, Refused, Don't Know, Not Ascertained
Yes, Yes but no information, No, Refused, Don't Know, Not
Ascertained
Yes, Yes but no information, No, Refused, Don't Know, Not
Ascertained
Yes, Yes but no information, No, Refused, Don't Know, Not
Ascertained
Yes, Yes but no information, No, Refused, Don't Know, Not
Ascertained
Yes, Yes but no information, No, Refused, Don't Know, Not
Ascertained
Yes, Yes but no information, No, Refused, Don't Know, Not
Ascertained
Mentioned, Not Mentioned, Refused, Don't Know, Not
Ascertained Yes, Yes but no information, No, Refused, Don't Know, Not
Ascertained
Not covered, covered, refused, don't know, not ascertained
Less than 8th grade, 9th-12th grade, HS or GED, AA, some
college, Bachelors, masters, doctoral, Refused, Don't Know, Not
Ascertained
$0-4,999, $5,000-$9,999, $10,000-$14,999, $15,000-$19,999,
$20,000-$24,999, $25,000-$29,999, $30,000-$34,999, $35,000$39,999, $40,000-$44,999, $45,000-$54,999, $55,000-$64,999,
$65,000-$74,999, over $75,000, Refused, Don't Know, Not
Ascertained
Yes,No, Refused, Don't Know, Not Ascertained
Yes,No, Refused, Don't Know, Not Ascertained
Yes,No, Refused, Don't Know, Not Ascertained
Yes,No, Refused, Don't Know, Not Ascertained
Excellent, Very Good, Good, Fair, Poor, Refused, Don't Know,
Not Ascertained
Yes,No, Refused, Don't Know, Not Ascertained
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Place to go when sick

Doctor's office, clinic, hospital ER, hospital outpatient, some other
place, doesn't go to one place, refused, don't know, not ascertained

Currently taking birth
control pills, implants, or
shots
Seen/talked to doctor in
past 12 months
Seen/talked to OB/GYN in
past 12 months
Flu shot past 12 months
Hepatitis A vaccine - ever
(Y,N)
Hepatitis B vaccine - ever
(Y,N)
Tetanus shot in past 10
years (Y,N)
Had STD past 5 years
Saw a doctor for STD
Ever been tested for HIV
(Y,N)
Heard of HPV
Heard of HPV vaccine/shot

Yes,No, Refused, Don't Know, Not Ascertained

Yes,No, Refused, Don't Know, Not Ascertained
Yes,No, Refused, Don't Know, Not Ascertained
Yes,No, Refused, Don't Know, Not Ascertained
Yes,No, Refused, Don't Know, Not Ascertained
Yes,No, Refused, Don't Know, Not Ascertained
Yes,No, Refused, Don't Know, Not Ascertained
Yes,No, Refused, Don't Know, Not Ascertained
Yes,No, Refused, Don't Know, Not Ascertained
Yes,No, Refused, Don't Know, Not Ascertained
Yes,No, Refused, Don't Know, Not Ascertained
Yes,No, Refused, Don't Know, Not Ascertained
Yes,No, Refused, Don't Know, Not Ascertained
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Table 2. Selected Sample Characteristics of non-vaccinated women (n=1,458)*
Characteristic
Age
18-20
21-23
24-26
Insurance Coverage
Yes
No
Married
Yes
no
Race/ethnicity
Hispanic
non-Hispanic white
non-Hispanic black
non-Hispanic other
Region
Northeast
Midwest
South
West
Education
Less than high school
High school
Some college
College or higher
Annual Income
0-19,999
20,000-34,999
≥35,000
Given birth in past 5 years
Yes
no
Currently on birth control
Yes
no
Ever had Pap test

%

N

37

322
528
608

22.1
36.2
41.7

1041
412

75.4
28.3

315
1140

21.6
78.2

366
685
296
111

24.0
46.9
20.3
7.6

188
325
566
379

12.9
22.3
38.8
25.7

242
377
576
260

16.6
25.9
39.6
17.9

759
241
116

52.1
16.5
8.0

540
918

37.0
62.9

452
999

31.0
68.5

Yes
1139
78.1
no
312
21.4
Seen a doctor in past year
Yes
785
53.8
No
672
46.1
Flu shot last 12 months
Yes
159
17.6
No
744
82.5
Tetanus shot last 10 years
Yes
871
59.7
No
535
36.7
Hepatitis A vaccine
Yes
345
23.7
no
927
63.6
Hepatitis B vaccine
Yes
805
55.2
No
556
38.1
* Some totals may not add up to 100% due to missing responses to deleted categories
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Table 3. HPV Vaccine Attitudes and Awareness of Non-Vaccinated Women*
%
Question
n
Heard of HPV (n=1458)
Yes
1089 74.7
No
368 25.2
Heard of HPV vaccine (n=1458)
Yes
954 65.4
No
504 34.6
Interested in getting HPV vaccine (n=1458)
Yes
480 32.9
No
917 62.9
Would get vaccine if the cost was $360-500 (n=408)
Yes
96 20.0
No
377 78.5
Would get vaccine if free or lower cost (n=404)
Yes
386 95.5
No
11 2.7
Main reason would not get HPV vaccine (n=988)
does not need vaccine
395 40.4
not sexually active
70 7.20
too expensive
27 2.8
too old for vaccine
28 2.9
doctor didn't recommend it
76 7.8
worried about safety of vaccine
106 10.8
don't know where to get vaccine
3 0.3
my spouse/family member is against it
4 0.4
don’t know enough about the vaccine
132 13.5
already have HPV
25 2.6
* Some totals may not add up to 100% due to missing responses
or deleted categories
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Table 4. Selected Sample Characteristics of Vaccinated Women (n=408)*
%
Characteristic
N
Age
18-20
170
41.6
21-23
135
33.1
24-26
103
25.2
Insurance Coverage
Yes
340
83.9
No
65
16.1
Married
Yes
45
11.03
no
363
88.9
Race/ethnicity
Hispanic
82
20.1
non-Hispanic white
230
56.3
non-Hispanic black
71
17.4
non-Hispanic other
25
6.1
Region
Northeast
54
13.2
Midwest
108
26.4
South
129
31.6
West
117
28.6
Education
Less than high school
46
11.2
High school
82
48.2
Some college
197
48.2
College or higher
83
20.3
Annual Income
0-19,999
180
61.4
20,000-34,999
47
16.0
≥35,000
66
22.5
Given birth in past 5 years
Yes
82
20.1
no
326
79.9
Currently on birth control
Yes
205
50.3
no
202
49.6
Ever had Pap test
40

Yes
332
81.5
no
75
18.4
Seen a doctor in past year
Yes
291
71.3
No
117
28.6
Flu shot last 12 months
Yes
78
37.1
No
132
62.8
Tetanus shot last 10 years
Yes
317
81.2
No
73
18.7
Hepatitis A vaccine
Yes
152
43.1
no
201
56.9
Hepatitis B vaccine
Yes
263
75.4
No
92
24.5
* Some totals may not add up to 100% due to missing responses to deleted categories
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Table 5. Summary of Bivariate Associations between Potential
Predictors and Non-vaccination
Variable Grouping
p value
Demographic Variables
Race Recode (white, not white)
Race/Ethnicity (Hispanic, White, NonHispanic Black, Other)
Hispanic Ethnicity (Yes, No)
Marital Status (Married, not married)
Born in US (Y,N)
Language (English, Other)
Region
Age
Live birth within past 5 years

0.048*
0.0098*
0.0369*
<.0001*
0.0057*
0.0006*
0.0519*
<.0001*
<.0001*

Socioeconomic Variables
Medicaid (Y,N)
Medicare
SCHIP coverage
State-sponsored health plan
Other government health
plan
Military health care
coverage
Ineligible because of
age/school
Private Insurance (Y,N)
No Coverage (Y,N)
Education (<HS, HS, some college,
≥college)
College Education (Y, N)
Total earnings last year
Full time work (Y,N)

0.0448*
<.0001*
<.0001*
0.0006*
<.0001*
0.3522
-

Health Utilization
Pap test ever (Y, N)
Abnormal Pap test results past 3 years (Y, N)
Told by doctor had HPV

0.177*
0.0761*
0.0022*
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(Y,N)
Reported Health Status
(Excellent/Very good vs.
Good/Fair/Poor)
Has usual Place to go when
sick (Y, N)
Place to go when sick
(doctor's office/clinic vs.
other)
Currently taking birth
control pills, implants, or
shots (Y,N)
Seen/talked to doctor in past
12 months (Y,N)
Seen/talked to OB/GYN in
past 12 months (Y,N)
Flu shot past 12 months
(Y,N)
Hepatitis A vaccine - ever
(Y,N)
Hepatitis B vaccine - ever
(Y,N)
Tetanus shot in past 10 years
(Y,N)
Had STD past 5 years (Y,N)
Saw a doctor for STD (Y,N)
Ever been tested for HIV
(Y,N)

0.2602

<.0001*
0.8058

<.0001*

<.0001*
0.2211*

<.0001*
<.0001*
<.0001*
<.0001*
0.1062*
0.2711

Knowledge
Heard of HPV (Y, N)
Heard of HPV vaccine/shot
(Y,N)
* variables significant at exploratory level of p<.20
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<.0001
-
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45

46

47

Table 10. Full Model (N=1,041; no=846, yes=195)
Variable
aOR
95% CI
p
SE
Age
18-21 (ref)
22-25
3.39 2.26-5.09 <.0001 0.20
26
1.82 1.01-3.28
0.045 0.30
Marital Status
1.83 1.04-3.21
0.036 0.28
No insurance
1.60 0.97-2.62
0.061 0.25
College education
0.69 0.46-1.05 0.0867 0.21
Region
South (ref)
Northeast
0.64 0.36-1.13 0.1305 0.28
Midwest
0.64 0.39-1.03 0.0697 0.24
West
0.48 0.30-0.77 0.0027 0.24
Usual place of care
0.78 0.47-1.31 0.3594 0.26
Live birth in past 5 years
2.62 1.59-4.29 0.0001 0.25
Currently on birth control
0.46 0.32-0.66 <.0001 0.18
Doctor visit past 12 months
0.64 0.42-0.97 0.0352 0.20
Flu shot in past year
0.35 0.23-0.52 <.0001 0.20
Tetanus shot in past 10 years
0.44 0.28-0.69 0.0004 0.23
model chi-square (LR)=213.55 (14), p=<.0001
Hosmer-Lemeshow chi square=7.84 (8), p=.448
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Table 11: Final Model (N=1067; no=868, yes=199)
Variable
aOR
95% CI
p
Age
18-21 (ref)
22-25
2.93 2.00-4.30 <.0001
26
1.49 0.85-2.61
0.156
Married
1.75 1.02-3.01
0.042
Region
South (ref)
Northeast
0.65 0.38-1.14
0.136
Midwest
0.65 0.41-1.04
0.077
West
0.50 0.31-0.79
0.003
Live birth in past five years
2.77 1.75-4.39 <.0001
Currently on birth control
0.45 0.31-0.64 <.0001
Doctor visit past year
0.57 0.39-0.84 0.0045
Flu shot in past year
0.36 0.24-0.54 <.0001
Tetanus shot in past 10 years 0.40 0.26-0.62 <.0001
model chi-square (LR)=193.30 (11), p=<.0001
Hosmer-Lemeshow chi square=14.41(8), p=.071
Max Rescaled R-square=0.268
Percent Concordant=79.1
Percent Discordant=20.2
c=.795
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SE

0.19
0.28
0.27

0.27
0.23
0.23
0.23
0.17
0.19
0.20
0.22
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Table 14: Backwards Elimination Procedure (N=1,063; no=864, yes=199)
Variable
aOR
95% CI
p
SE
Not covered
1.70
1.06-2.72
0.027
0.24
Age
18-21 (ref)
22-25
2.91
1.99-4.27
<.0001
0.19
26
1.51
0.86-2.65
0.14
0.28
Married
1.81
1.06-3.17
0.028
0.27
Region
South (ref)
Northeast
0.68
0.39-1.18
0.175
0.28
Midwest
0.67
0.42-1.07
0.099
0.23
West
0.49
0.31-0.78
0.002
0.23
Live birth
2.67
1.69-4.23
<.0001
0.23
birth control pills
0.46
0.32-0.61
<.0001
0.17
doctor visit past year
0.63
0.43-0.93
0.021
0.02
Flu shot
0.36
0.24-0.54
<.0001
0.20
Tetanus shot
0.42
0.27-0.66
0.0002
0.22
model chi-square (LR)=198.05 (12), p=<.0001
Hosmer-Lemeshow chi square=10.24(8), p=.247
Max Rescaled R-square=0.27
Percent Concordant=79.3
Percent Discordant=20.0
c=.797
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53
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Table 17. 2011 Cross-Validation Model (N=2,220; no=1568, yes=639)
Variable
aOR
95% CI
p
SE
Age
18-24 (ref)
25
1.61 1.19-2.19
.0021 0.15
26
2.42 1.70-3.43 <.0001 0.17
Married
2.38 1.78-3.19 <.0001 0.14
Region
South (ref)
Northeast
0.55 0.41-0.75
.0002 0.15
Midwest
0.78 0.61-1.01
0.06 0.12
West
0.78 0.60-1.00
0.05 0.12
Doctor visit past year
0.62 0.51-0.77 <.0001 0.10
Flu shot in past year
0.60 0.49-0.75 <.0001 0.11
Tetanus shot in past 10 years
0.46 0.36-0.58 <.0001 0.10
model chi-square (LR)=222.86 (11), p=<.0001
Hosmer-Lemeshow chi square=2.80(8), p=.94
Max Rescaled R-square=0.137
Percent Concordant=68.6
Percent Discordant=29.2
c=.696
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Figure 1: Odds Ratio Plot for Age

Odds Ratio Estimates
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18
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18
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Figure 2: ROC Curve Final Model

b
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Figure 3: ROC Curve Backwards Elimination Model
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Figure 4: ROC Curve 2011 Cross-Validation Model
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